首页> 外文期刊>Modern Pathology >Metanephric adenoma: the utility of immunohistochemical and cytogenetic analyses in differential diagnosis, including solid variant papillary renal cell carcinoma and epithelial-predominant nephroblastoma
【24h】

Metanephric adenoma: the utility of immunohistochemical and cytogenetic analyses in differential diagnosis, including solid variant papillary renal cell carcinoma and epithelial-predominant nephroblastoma

机译:后肾腺瘤:免疫组织化学和细胞遗传学分析在鉴别诊断中的应用,包括实体变型乳头状肾细胞癌和上皮占优势的肾母细胞瘤

获取原文
           

摘要

Metanephric adenoma is a benign renal neoplasm that overlaps in morphology with the solid variant of papillary renal cell carcinoma and epithelial-predominant nephroblastoma. To aid in resolving this differential diagnosis, we investigated the utility of immunohistochemical and molecular analyses in distinguishing between these entities; the first study, to our knowledge, to use a combined approach in analyzing all three tumors. We analyzed 37 tumors originally diagnosed as metanephric adenomas (2 of which we reclassified as papillary renal cell carcinomas), 13 solid variant papillary renal cell carcinomas, and 20 epithelial-predominant nephroblastomas using a combination of immunohistochemistry and fluorescence in situ hybridization (FISH) assessing for trisomy of chromosomes 7 and 17 and loss of Y. Immunohistochemical staining was performed for CK7, AMACR, WT1, and CD57. The combination of CK7鈥? AMACR鈥? WT1+, and CD57+ was considered characteristic of metanephric adenoma. Most of the tumors originally diagnosed as metanephric adenomas (31/37) showed the expected staining pattern of metanephric adenoma (CK7鈭? AMACR鈥? WT1+, and CD57+). Of the six tumors with discordant immunophenotype, two tumors were reclassified as papillary renal cell carcinoma after cytogenetic workup. It is recommended that all adult cases histologically resembling metanephric adenoma have WT1, CD57, CK7, and AMACR immunohistochemical staining performed. If the staining pattern is characteristic for metanephric adenoma (CK7鈥? AMACR鈥? WT1+, and CD57+, including membranous staining), then no other diagnostic tests are indicated. However, if there is a different immunostaining pattern, then we recommend FISH analysis.
机译:后肾腺瘤是一种良性肾肿瘤,在形态上与乳头状肾细胞癌和上皮占优势的肾母细胞瘤的实体变型重叠。为了帮助解决这种鉴别诊断,我们研究了免疫组织化学和分子分析在区分这些实体中的效用。据我们所知,第一项研究是使用组合方法分析所有三种肿瘤。我们使用免疫组织化学和荧光原位杂交(FISH)进行了评估,分析了37例最初被诊断为后肾腺瘤的肿瘤(其中2例被重新分类为乳头状肾细胞癌),13例实体变型乳头状肾细胞癌和20例上皮性为主的肾母细胞瘤。对于染色体7和17的三体性和Y的损失。对CK7,AMACR,WT1和CD57进行免疫组织化学染色。 CK7的组合AMACR的? WT1 +和CD57 +被认为是后肾腺瘤的特征。最初被诊断为后肾腺瘤的大多数肿瘤(31/37)表现出预期的后肾腺瘤染色模式(CK7→AMACR→WT1 +和CD57 +)。在六种免疫表型不一致的肿瘤中,有两个肿瘤在细胞遗传学检查后被重新分类为乳头状肾细胞癌。建议所有组织学上类似后肾腺瘤的成年病例均需进行WT1,CD57,CK7和AMACR免疫组织化学染色。如果染色模式是肾上腺腺瘤的特征(CK7'AMACR'WT1 +和CD57 +,包括膜状染色),则无需进行其他诊断测试。但是,如果存在不同的免疫染色模式,则建议进行FISH分析。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号